Abbott to Pay $385 Million to Resolve Claims Over Michigan Formula Plant - WOWO News/Talk 92.3 FM and 1190 AM
Abbott Laboratories will pay $385 million to resolve claims related to contamination at its Michigan infant formula plant, including a 2022 recall. The settlement does not admit fault. The plant's closure contributed to a nationwide formula shortage. The DOJ's criminal investigation has closed. Abbott's Similac brand was among those recalled.
How this was made
The 30-second read
Why it matters
The $385 M settlement ends pending legal exposure and may slightly depress earnings, but removes ongoing litigation uncertainty.
Market read
Primary corporate news for ABT with modest trading impact; sector peers may see slight sentiment spillover.
What to watch
Abbott's insurance coverage and potential tax benefits from the settlement may mitigate the net financial hit.
Background
Abbott's Sturgis, Michigan plant was shut down in early 2022 after a recall of powdered infant formula, contributing to a national shortage.
Ticker impact
Abbott Laboratories agreed to pay $385 million to settle claims over its Michigan infant formula plant contamination.
Potential short‑term downside pressure of 1‑2% pending market reaction.
A $385 M cash outflow is material for a large cap health‑care company and could affect quarterly results.
Market effects
May raise scrutiny on infant formula manufacturers and could affect peer stocks in consumer health.
Limited to U.S. health‑care sector; no broad regional effect.
Low global relevance beyond the U.S. market.
Counterpoint
The settlement resolves all litigation risk, potentially clearing the way for smoother operations and could be priced in already.
Key entities
- CompanyAbbott Laboratories
U.S. health‑care company producing infant formula.
- GovernmentU.S. Justice Department
Closed its criminal investigation into the plant.
